Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer

被引：0
|
作者：
Hirotoshi Ishiwatari
Tsuyoshi Hayashi
Makoto Yoshida
Michihiro Ono
Tsutomu Sato
Koji Miyanishi
Yasushi Sato
Rishu Takimoto
Masayoshi Kobune
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Biliary tract cancer; Hepatic arterial infusion; Chemotherapy; S-1; Gemcitabine; Neutropenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：805 / 812
页数：7
相关论文
共 50 条
  • [1] Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer
    Ishiwatari, Hirotoshi
    Hayashi, Tsuyoshi
    Yoshida, Makoto
    Ono, Michihiro
    Sato, Tsutomu
    Miyanishi, Koji
    Sato, Yasushi
    Takimoto, Rishu
    Kobune, Masayoshi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 805 - 812
  • [2] A phase II trial of oral S-1 combined with gemcitabine in patients with unresectable biliary tract cancer
    Nakamura, K.
    Yamaguchi, T.
    Sudo, K.
    Hara, T.
    Denda, T.
    Azemoto, R.
    Ishihara, T.
    Tsuyuguchi, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer
    Tsuyoshi Hayashi
    Hirotoshi Ishiwatari
    Makoto Yoshida
    Tsutomu Sato
    Koji Miyanishi
    Yasushi Sato
    Masayoshi Kobune
    Rishu Takimoto
    Tomoko Sonoda
    Junji Kato
    International Journal of Clinical Oncology, 2012, 17 : 491 - 497
  • [4] A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer
    Hayashi, Tsuyoshi
    Ishiwatari, Hirotoshi
    Yoshida, Makoto
    Sato, Tsutomu
    Miyanishi, Koji
    Sato, Yasushi
    Kobune, Masayoshi
    Takimoto, Rishu
    Sonoda, Tomoko
    Kato, Junji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (05) : 491 - 497
  • [5] Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
    Kanai, Masashi
    Hatano, Etsuro
    Kobayashi, Syogo
    Fujiwara, Yutaka
    Sakai, Daisuke
    Kodama, Yuzo
    Ajiki, Tetsuo
    Nagano, Hiroaki
    Ioka, Tatsuya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1181 - 1188
  • [6] Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
    Masashi Kanai
    Etsuro Hatano
    Syogo Kobayashi
    Yutaka Fujiwara
    Daisuke Sakai
    Yuzo Kodama
    Tetsuo Ajiki
    Hiroaki Nagano
    Tatsuya Ioka
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1181 - 1188
  • [7] Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
    Kobayashi, Shogo
    Kanai, Masashi
    Hatano, Etsuro
    Fujiwara, Yutaka
    Sakai, Daisuke
    Kodama, Yuzo
    Ajiki, Tetsuo
    Nagano, Hiroaki
    Ioka, Tatsuya
    HEPATOLOGY, 2012, 56 : 470A - 471A
  • [8] Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    Nakamura, K
    Yamaguchi, T
    Ishihara, T
    Kobayashi, A
    Tadenuma, H
    Sudo, K
    Kato, H
    Saisho, H
    BRITISH JOURNAL OF CANCER, 2005, 92 (12) : 2134 - 2139
  • [9] Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    K Nakamura
    T Yamaguchi
    T Ishihara
    A Kobayashi
    H Tadenuma
    K Sudo
    H Kato
    H Saisho
    British Journal of Cancer, 2005, 92 : 2134 - 2139
  • [10] Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer
    Shoji, Hirokazu
    Morizane, Chigusa
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Ueno, Hideki
    Takahashi, Hideki
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Okusaka, Takuji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (02) : 132 - 137
12345